Search

Your search keyword '"Thompson, Christopher C."' showing total 3,083 results
Start Over Author "Thompson, Christopher C."
3,083 results on '"Thompson, Christopher C."'

10. American Society for Gastrointestinal Endoscopy–European Society of Gastrointestinal Endoscopy guideline on primary endoscopic bariatric and metabolic therapies for adults with obesity

Author

Jirapinyo, Pichamol, Hadefi, Alia, Thompson, Christopher C., Patai, Árpád V., Pannala, Rahul, Goelder, Stefan K., Kushnir, Vladimir, Barthet, Marc, Apovian, Caroline M., Boskoski, Ivo, Chapman, Christopher G., Davidson, Paul, Donatelli, Gianfranco, Kumbhari, Vivek, Hayee, Bu, Esker, Janelle, Hucl, Tomas, Pryor, Aurora D., Maselli, Roberta, Schulman, Allison R., Pattou, Francois, Zelber-Sagi, Shira, Bain, Paul A., Durieux, Valérie, Triantafyllou, Konstantinos, Thosani, Nirav, Huberty, Vincent, and Sullivan, Shelby

Published
2024
Full Text
View/download PDF

12. Endoscopic Management of Bariatric Complications

Author

Brunaldi, Vitor Ottoboni, Thompson, Christopher C., Galvao Neto, Manoel, Nguyen, Ninh T., editor, Clarke, John O., editor, Lipham, John C., editor, Chang, Kenneth J., editor, Schnoll-Sussman, Felice, editor, Bell, Reginald C.W., editor, and Kahrilas, Peter J., editor

Published
2023
Full Text
View/download PDF

29. Aspiration therapy for the treatment of obesity: 4-year results of a multicenter randomized controlled trial

Author

Thompson, Christopher C, Abu Dayyeh, Barham K, Kushnir, Vladimir, Kushner, Robert F, Jirapinyo, Pichamol, Schorr, Alan B, Aronne, Louis J, Amaro, Anastassia, Jaffe, David L, Schulman, Allison R, Early, Dayna, Stein, Adam C, Sharaiha, Reem, Edmundowicz, Steven A, Bohning, J Matthew, Jensen, Michael D, Shukla, Alpana P, Apovian, Caroline, Kim, Dong Wook, Tran, Daniel, Zarrinpar, Amir, Ryan, Michele B, Young, Meredith, Lowe, Abigail, Haas, Miki, Goldsmith, Heidi, McCrea, Jennifer, and Sullivan, Shelby

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Patient Safety, Digestive Diseases, Clinical Research, Nutrition, Prevention, Behavioral and Social Science, Obesity, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Oral and gastrointestinal, Cancer, Metabolic and endocrine, Adult, Bariatric Surgery, Body Mass Index, Drainage, Endoscopy, Gastrointestinal, Gastrostomy, Humans, Middle Aged, Obesity, Morbid, Treatment Outcome, Weight Loss, Endoscopic bariatric therapy, Aspiration therapy, Metabolic, Diet, Public Health and Health Services, Surgery, Clinical sciences, Public health
Abstract

BackgroundThe AspireAssist is the first Food and Drug Administration-approved endoluminal device indicated for treatment of class II and III obesity.ObjectivesWe earlier reported 1-year results of the PATHWAY study. Here, we report 4-year outcomes.SettingUnited States-based, 10-center, randomized controlled trial involving 171 participants with the treatment arm receiving Aspiration Therapy (AT) plus Lifestyle Therapy and the control arm receiving Lifestyle Therapy (2:1 randomization).MethodsAT participants were permitted to continue in the study for an additional year up to a maximum of 5 years providing they maintained at least 10% total weight loss (TWL) from baseline at each year end. For AT participants who continued the study, 5 medical monitoring visits were provided at weeks 60, 68, 76, 90, and 104 and thereafter once every 13 weeks up to week 260. Exclusion criteria were a history of eating disorder or evidence of eating disorder on a validated questionnaire. Follow-up weight, quality of life, and co-morbidities were compared with the baseline levels. In addition, rates of serious adverse event, persistent fistula, withdrawal, and A-tube replacement were reported. All analyses were performed using a per-protocol analysis.ResultsOf the 82 AT participants who completed 1 year, 58 continued to this phase of the trial. Mean baseline body mass index of these 58 patients was 41.6 ± 4.5 kg/m2. At the end of first year (at the beginning of the follow-up study), these 58 patients had a body mass index of 34.1 ± 5.4 kg/m2 and had achieved an 18.3 ± 8.0% TWL. On a per protocol basis, patients experienced 14.2%, 15.3%, 16.6%, and 18.7% TWL at 1, 2, 3, and 4 years, respectively (P < .01 for all). Forty of 58 patients (69%) achieved at least 10% TWL at 4 years or at time of study withdrawal. Improvements in quality of life scores and select cardiometabolic parameters were also maintained through 4 years. There were 2 serious adverse events reported in the second through fourth years, both of which resolved with removal or replacement of the A tube. Two persistent fistulas required surgical repair, representing approximately 2% of all tube removals. There were no clinically significant metabolic or electrolytes disorders observed, nor any evidence for development of any eating disorders.ConclusionsThe results of this midterm study have shown that AT is a safe, effective, and durable weight loss alternative for people with class II and III obesity and who are willing to commit to using the therapy and adhere to adjustments in eating behavior.

Published
2019

37. Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial

Author

Acosta, Andres J, Badurdeen, Dilhana, Buttar, Navtej S, Clark, Matthew M, Eaton, Laura, Ghanem, Omar, Grothe, Karen, Jirapinyo, Pichamol, Kellogg, Todd, Klein, Connie L, Mundi, Manpreet, Storm, Andrew C, Rivera, Angielyn R, Wilson, Todd D, Abu Dayyeh, Barham K, Bazerbachi, Fateh, Vargas, Eric J, Sharaiha, Reem Z, Thompson, Christopher C, Thaemert, Bradley C, Teixeira, Andre F, Chapman, Christopher G, Kumbhari, Vivek, Ujiki, Michael B, Ahrens, Jeanette, Day, Courtney, Galvao Neto, Manoel, Zundel, Natan, and Wilson, Erik B

Published
2022
Full Text
View/download PDF

43. Glucagon-like peptide-1 receptor agonists before upper gastrointestinal endoscopy and risk of pulmonary aspiration or discontinuation of procedure: cohort study.

Author

Alkabbani, Wajd, Suissa, Karine, Gu, Kristine D., Cromer, Sara J., Paik, Julie M., Bykov, Katsiaryna, Hobai, Ion, Thompson, Christopher C., Wexler, Deborah J., and Patorno, Elisabetta

Subjects
RESPIRATORY aspiration -- Risk factors, GLUCAGON-like peptide-1 agonists, RISK assessment, RESEARCH funding, TERMINATION of treatment, PROBABILITY theory, RELATIVE medical risk, DESCRIPTIVE statistics, LONGITUDINAL method, ENDOSCOPIC gastrointestinal surgery, SODIUM-glucose cotransporter 2 inhibitors, TYPE 2 diabetes, COMPARATIVE studies, CONFIDENCE intervals
Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results